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Abstract
Background: Tropical infectious diseases are called neglected, because they are, inter alia, characterized by an R&D
deficit. A similar deficit exists for rare (orphan) diseases which neither promise a sufficient return on R&D
investment. To encourage the development of treatments for rare diseases, orphan drug acts were created which
contain financial and non-financial incentives for the pharmaceutical industry. Similar instruments aimed exclusively
at neglected diseases do not yet exist. Proposals for a regulatory approach to promote R&D for neglected diseases
include the application of selected orphan drug incentives, or the implementation of a Medical Research and
Development Treaty (MRDT) with national funding obligations for medical R&D. We compiled and analyzed
experts’ opinions on causes for the treatment deficit for neglected diseases and on desirable and feasible measures
to promote neglected disease R&D. Hereby, the focus was on mechanisms contained in orphan drug regulations
and in the Medical Research and Development Treaty draft (Discussion draft 4, 2005). Lastly, we solicited experts’
opinions on the desirability and feasibility of a regulatory instrument to foster R&D for neglected diseases.
Methods: An international online-Delphi survey was conducted with 117 (first round) and 56 (second round)
experts of different professional backgrounds and professional affiliations who formulated and ranked causes and
solutions related to the treatment deficit for neglected diseases.
Results: In both rounds of survey, the majority of the participating experts (88.4% first round, 86.8% second round)
advocated the development of a regulatory instrument to promote R&D for neglected diseases. Most experts
(77.9% first round, 79.3% second round) also considered this to be a feasible option. With the exception of market
exclusivity, which was viewed critically, key provisions contained in orphan drug regulations were judged favorably
also for neglected diseases. A majority (87.1% first round, 77.2% second round) supported national funding
obligations for neglected diseases which are proposed by the Medical Research and Development Treaty draft.
Conclusions: While not all features of orphan drug regulations and of the MRDT draft received equal support, the
view was expressed that a regulatory instrument would be a desirable and feasible measure to promote R&D for
neglected diseases.
Background
About one billion people worldwide suffer from so-called
neglected diseases (NDs). Neglected diseases are a hetero-
geneous [1] group of predominantly, but not exclusively,
tropical infectious diseases, such as Buruli ulcer, Blinding
Trachoma, Dengue and Dengue Hemorrhagic Fever, Lym-
phatic Filariasis, Human African Trypanosomiasis, Oncho-
cerciasis, or Schistosomiasis (a list of 15 NDs is available
on http://www.who.int/neglected_diseases/diseases/en/).
Common features of neglected diseases include their pre-
valence in poor populations in developing countries, their
cause for stigma and discrimination, their high impact on
morbidity and mortality and their relative neglect in terms
of research and development activities. For some neglected
diseases, tools are available to control, prevent or possibly
eliminate them. For other so-called tool-deficient diseases,
such tools are still lacking [2,3]. With their often chronic
and crippling character, neglected diseases cause immense
suffering for the individual patient. Their accumulated
prevalence puts a severe strain on the affected societies,
with serious and long-lasting social and economic adverse
effects on the endemic regions [3]. Substandard living
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any medium, provided the original work is properly cited.conditions, lack of clean water, sanitary facilities and
access to health care contribute to their spread and persis-
tence. Poverty, equivalent to the absence of purchasing
power, is considered the main cause for the structural defi-
cit that exists for drug R&D into neglected diseases
[2,4-12]. The World Health Organization (WHO) there-
fore not only speaks of neglected diseases, but also of
“neglected populations” [13]. Owing to the lack of a mar-
ket perspective for pharmaceutical products, R&D efforts
for neglected diseases are not proportionate to the dis-
eases’ prevalence and their public health impact [14,15]. A
similar R&D deficit exists for rare diseases whose small
patient populations neither promise adequate returns on
investment [16-19]. Public health policy responded to the
treatment deficit for rare diseases with the adoption of
orphan drug acts, i.e. regulatory instruments with financial
and non-financial incentives for the pharmaceutical indus-
try. Comparable legislation focusing on neglected diseases
does not yet exist, even though tropical infectious diseases
had originally been included both in the concept of “drugs
of limited commercial value” [20] which formed the basis
for the U.S. Orphan Drug Act, and in early drafts for the
European legislation [21]. The first Orphan Drug Act
(ODA) was adopted in 1983 in the United States [22], fol-
lowed by similar legislation in Australia, Japan and, in the
year 2000, in the European Union [23]. One incentive of
orphan drug legislation is several years of market exclusiv-
ity for orphan products. Additionally, sponsors of desig-
nated orphan products benefit from fee waivers, protocol
assistance and, under the U.S. Orphan Drug Act, from
grants and tax credits.
The perceived commonality of rare and neglected dis-
eases, i.e. structural R&D deficits, has nourished a long-
standing debate whether orphan drug incentives may also
benefit neglected diseases. Owing to their reliance on mar-
ket exclusivity, however, along with liberty of pricing,
orphan drug acts have often been considered ineffective or
inappropriate for neglected diseases [21,24-26].
A different regulatory approach to promote R&D for
neglected diseases is included in the Medical Research
and Development Treaty draft [27]. This document,
which was submitted to the WHO Commission on Intel-
lectual Property, Innovation and Public Health (CIPIH)
in February 2005 [28], does not exclusively address R&D
for neglected diseases; instead, it aims to restructure
funding for medical research and development entirely,
whereby diseases of poverty are given particular atten-
tion. Proceeding from the notion that the current system
of funding for medical R&D, based on patents and high
drug prices to recoup investment, is ineffective, expensive
and does not respond to public health needs [28], the
authors and sponsors of the Treaty propose national
funding obligations for medical R&D based on GDP or
per capita income [27].
Both orphan drug-style incentives and the proposed
Medical Research and Development Treaty continue to
occupy a prominent place in the debate on promoting
R&D into neglected diseases [26,29]. Therefore, we con-
sidered it timely and of relevant public health interest to
explore among experts the desirability and feasibility of
a regulatory instrument and of a selection of mechan-
isms and incentives contained therein.
Methods
The survey was based on the concept of a Policy Delphi.
A Policy Delphi aims to solicit as many different views
on an issue as possible to provide decision makers with
the broad spectrum of aspects that have to be considered
in a decision-making process [30]. To this end, it follows
the characteristic Delphi process of anonymous rounds
of survey with feedbacks after each round. A Policy Del-
phi usually involves three to five rounds, with extensive
analyses of dissensions. Guidelines for its implementation
recommend i.a. at least two professionals to design/
monitor the exercise, sometimes prior development of
scenarios, factual summaries of background information,
pre-tests, presenting respondents their original vote, as
well as ensuring that the panel represents a peer group.
As Turoff predicts for Policy Delphis, where “the respon-
dents feel strongly about the issues, and this should be
the case, [...]”, “[...] the questionnaire for the second
r o u n dw i l lb ef i v et ot e nt i m e st h a to ft h ef i r s tr o u n d . ”,
acknowledging that the items that were contributed later
do not receive the same treatment as those listed from
the beginning of the survey [30]. We designed the survey
based on these guidelines, yet limited the number of
rounds to two, with utmost effort devoted to the analysis
of suggestions received between the rounds. The ques-
tionnaire for the first round was pretested and the initial
invitation to participate in the survey was accompanied
by a brief project description. The respondents were not
shown their votes from previous rounds, though, as this
would have required that their anonymity vis-à-vis the
research team is lifted; we decided to maintain anonymity
as we had stated.
A literature search and document analysis preceded
the design of the questionnaire for the first round of
survey. Five individuals of different academic back-
grounds pretested the first questionnaire and contribu-
ted 21 technical and editorial comments. 530 potential
participants were initially identified of whom we
attempted to contact 388 experts. The following sources
were used to compile the panel of experts:
￿ Publications on neglected and orphan diseases
￿ Participants in the Conference on Neglected Infec-
tious Diseases, organized by the DG Research of the
European Commission, Brussels, November 8 and 9,
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health/infectious-diseases/neglected-diseases/pdf/nid-
conference-final-report052007_en.pdf
￿ Contributions to two online hearings (November
1-15, 2006 and August 15 - September 30, 2007) of
the WHO Intergovernmental Working Group
(WHO-IGWG) to develop a global strategy and plan
of action for neglected diseases http://www.who.int/
phi/public_hearings/en/
￿ A letter signed by 162 scientists, public health
experts, lawyers, economists, government representa-
tives and parliamentarians to accompany the submis-
sion of the Medical Research and Development
Treaty draft to the WHO Commission on Intellec-
tual Property, Innovation and Public Health in 2005.
T h es u r v e yw a sc o n d u c t e do n l i n ei nt w or o u n d s
(March 8-April 3, 2008 and July 10-August 15, 2008; see
Additional File 1 Additional File 2: Questionnaires
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[31]. In total, the questionnaires contained seven (six in
the second round) closed-ended questions, nine full-text
fields for items to be added to the questionnaire, one
closed-ended question with three options for reply, two
hybrid questions and three (six in the second round) full-
text fields for general comments. In a qualitative analysis
[32] between the first and the second round, full-text
suggestions were structured and grouped into categories
from which new items were developed and incorporated
into the second-round questionnaire. Feedbacks, a key
feature of the Delphi process [33], consisted of graphic
illustrations of frequency analyses and of pdf-documents
with the contents of the nine full-text fields and the three
comment sections; both were integrated into the ques-
tionnaire for the second round and could be accessed via
links. Following the second and last round of the survey,
the experts received a link to the survey software to view
frequency distributions and comments of the second
round. This final feedback closed the exercise. The panel
was anonymous so that the replies could not be attribu-
ted to the survey participants. For reasons of anonymity,
intraindividual variations in the respondents replies
between the first and the second round of survey were
not tracked. Statistical analyses were performed using
Microsoft Excel and SPSS for tabular and graphic
presentation.
Results
Participation, attrition, demographic data
Of the 388 experts whom we attempted to contact, 159
experts initially agreed to participate in the first round of
the survey; of these, 117 fully completed the first ques-
tionnaire, and 56 the first and the second questionnaire.
Professional backgrounds of the experts in both rounds
were in medicine (36.4%/32.1%), public health (30.5%/
26.85%), biology/biomedical sciences (30.4%, only round
two), pharmaceutical sciences (17.9%, only round two),
law (8.5%/10.7%), political science (7.6%/12.5%), economy
(4.2%/0%), veterinary medicine (1.8%, only round two)
and ‘other’ (33.1%/8.9%). Multiple responses were possi-
ble; biology/biomedical sciences, pharmaceutical sciences
and veterinary medicine were added in the second round
based on full-text details given in the “other"-field during
the first round.
Data on professional affiliations of the experts for both
rounds revealed affiliations with academia (53.6%/
54.7%), industry (10.7%/11.3%), international organiza-
tions (4.5%/7.5%), national governments/parliaments
(5.4%/7.5%), non-governmental organizations (14.3%/
11.3%), public private partnerships (3.8%, only round
two) and ‘other’ (11.6%/3.8%). The category ‘public pri-
vate partnership’ was added in the second round follow-
ing full-text entries in the first round. Based on
publically available data for the 388 experts we initially
attempted to contact, we presumed that 48.2% (n = 187)
were from academia, 17.5% (n = 68) from national gov-
ernments/parliaments), 13.9% from non-governmental
organizations, 8.5% (n = 33) from industry, 8.3% (n =
32) from backgrounds we were unable to specify
(’other’), as well as 3.6% (n = 14) from international
organizations. Of the participants in both rounds, 74.8%
(75.5%) indicated their place of residency in a developed
country, 18.9% (20.8%) in a developing country, and
6.3% (3.8%) in a threshold country/emerging market.
To benefit from answers by experts who abandoned
the questionnaire during the course of the survey, fre-
quency distributions were based on N = 159 for the first
and N = 77 for the second round, with valid n calcu-
lated for each questionnaire item.
Causes for the treatment deficit for neglected diseases
The first chapter in both rounds of survey dealt with the
importance of likely causes for the treatment deficit for
neglected diseases. In the first round, seven causes,
retrieved from literature search and document analysis
were listed; following the experts’ suggestions for addi-
tional items, the list was expanded to 15 items in the
second round (Table 1).
The experts were rather agreed on the importance of
the causes, whereby in the first round of survey both
public and private funding deficits were rated slightly
more important than the lack of access to existing drugs,
inadequate R&D infrastructure in endemic countries or
the absence of effective drugs. In the second round of
survey, two newly-added causes, labeled ‘poverty as a dis-
ease-proliferating factor’ and ‘poverty as the reason for
market failure’, were considered the most important
causes for the treatment deficit; nearly equal importance
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Page 3 of 13Table 1 Causes for the treatment deficit for neglected diseases: Round I and II
% (n) % (n) % (n) % (n) % (n)
most
important
important unimportant least
important
no
judgment
Total valid
% (n)
Total N
(Missing)
No or insufficient sustainability of public funding for R&D for neglected diseases Round
I
40,3% (48) 47,9%
(57)
7,6% (9) 0,8% (1) 3,4% (4) 100,0%
(119)
159 (40)
Round
II
54,1% (33) 41,0%
(25)
3,3% (2) 1,6% (1) 0,0% (0) 100% (61) 77 (16)
No or inadequate direct public funding for research and development (R&D) for neglected
diseases
Round
I
35,2% (44) 60,0%
(75)
3,2% (4) 0,0% (0) 1,6% (2) 100,0%
(125)
159 (34)
Round
II
54,8% (34) 40,3%
(25)
4,8% (3) 0,0% (0) 0,0% (0) 100% (62) 77 (15)
No or inadequate incentives for the private sector to invest into R&D for neglected diseases Round
I
33,9% (42) 49,2%
(61)
8,9% (11) 4,8% (6) 3,2% (4) 100,0%
(124)
159 (35)
Round
II
41,9% (26) 45,2%
(28)
8,1% (5) 3,2% (2) 1,6% (1) 100% (62) 77 (15)
No or inadequate private sector investment into R&D for neglected diseases Round
I
33,6% (42) 58,4%
(73)
4,8% (6) 0,8% (1) 2,4% (3) 100,0%
(125)
159 (34)
Round
II
45,2% (28) 40,3%
(25)
4,8% (3) 8,1% (5) 1,6% (1) 100% (62) 77 (15)
No or inadequate access to effective drugs for neglected diseases Round
I
33,1% (40) 47,1%
(57)
9,1% (11) 8,3% (10) 2,5% (3) 100,0%
(121)
159 (38)
Round
II
41,0% (25) 47,5%
(29)
4,9% (3) 6,6% (4) 0,0% (0) 100% (61) 77 (16)
No or inadequate research infrastructure in countries with neglected diseases Round
I
29,5% (36) 55,7%
(68)
7,4% (9) 6,6% (8) 0,8% (1) 100,0%
(122)
159 (37)
Round
II
27,9% (17) 60,7%
(37)
8,2% (5) 3,3% (2) 0,0% (0) 100% (61) 77 (16)
No or ineffective drugs for neglected diseases Round
I
20,5% (24) 48,7%
(57)
15,4% (18) 8,5% (10) 6,8% (8) 100,0%
(117)
159 (42)
Round
II
30,0% (18) 58,3%
(35)
8,3% (5) 3,3% (2) 0,0% (0) 100% (60) 77 (17)
Disease-specific research difficulties (unknown etiology, lack of research material) Round
II
4,9% (3) 62,3%
(38)
18,0% (11) 11,5% (7) 3,3% (2) 100% (61) 77 (16)
No or inadequate research coordination Round
II
8,2% (5) 49,2%
(30)
32,8% (20) 6,6% (4) 3,3% (2) 100% (61) 77 (16)
Lack of awareness/visibility of neglected diseases Round
II
32,8% (20) 52,5%
(32)
13,1% (8) 1,6% (1) 0,0% (0) 100% (61) 77 (16)
Lack of health-needs driven priority setting in public funding Round
II
44,3% (27) 50,8%
(31)
4,9% (3) 0,0% (0) 0,0% (0) 100% (61) 77 (16)
No or inadequate health delivery infrastructure and staff in developing countries Round
II
45,9% (28) 41,0%
(25)
9,8% (6) 1,6% (1) 1,6% (1) 100% (61) 77 (16)
F
e
h
r
e
t
a
l
.
B
M
C
H
e
a
l
t
h
S
e
r
v
i
c
e
s
R
e
s
e
a
r
c
h
2
0
1
1
,
1
1
:
3
1
2
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
2
-
6
9
6
3
/
1
1
/
3
1
2
P
a
g
e
4
o
f
1
3Table 1 Causes for the treatment deficit for neglected diseases: Round I and II (Continued)
Inadequate research priorities in private sector R&D Round
II
48,4% (30) 37,1%
(23)
11,3% (7) 3,2% (2) 0,0% (0) 100% (62) 77 (15)
Poverty as reason for market failure (perception of no market for drugs, insufficient R&D) Round
II
55,0% (33) 35,0%
(21)
5,0% (3) 3,3% (2) 1,7% (1) 100% (60) 77 (17)
Poverty as disease-proliferating factor (i.a. inadequate prevention, inadequate housing, lack of
clean water) in endemic countries
Round
II
57,4% (35) 32,8%
(20)
6,6% (4) 3,3% (2) 0,0% (0) 100%(61) 77 (16)
The results for those items that were added to the second round of survey are shown in the lower part of the table
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3was attributed to the lack of (sustainable) public R&D
funding, which had been ranked first in the initial round
of survey. 13 of the 15 causes listed in the second round
were considered most important or important by more
than 80% of the panelists; only two items, i.e. disease-
specific research difficulties and no or inadequate
research coordination received less than 80% of aggre-
gated positive replies.
Orphan drug regulations for rare diseases
The first question in this section, which asked if and to
which extent the respondents were familiar with orphan
drug laws, served as a filter question. Experts with no
knowledge about these laws (n = 53) skipped the ques-
tion on their effectiveness, while those with active (n =
13) and with passive knowledge (n = 60) continued to the
assessment. 61.4% of the respondents rated orphan drug
regulations very effective or effective; of their individual
incentives, market exclusivity was given the highest rank-
ing (22.1%) in the category “very effective"; the highest
aggregated positive reply (very effective/effective) was
given to tax credits (62.3%). (Table 2)
Measures to promote R&D for neglected diseases
In the next chapter of the questionnaire, the participating
experts were requested to rank (according to desirability
and feasibility) a list of possible measures to promote
R&D for neglected diseases. Three key incentives con-
tained in orphan drug regulations, i.e. tax credits, fee
waivers and protocol assistance, or scientific advice, were
considered desirable and feasible to foster R&D for
neglected diseases by more than two thirds of the experts
in both rounds. (Table 3, Table 4)
National funding obligations for medical R&D and
prize funds proposed in the Medical Research and
Development Treaty draft were supported by a majority
of experts in both rounds; the concept of separating
innovation incentives from drug prices rendered slightly
more controversial results. Perhaps owing to the far-
reaching character of these paradigm changes, the sur-
vey participants were slightly cautious in predicting their
feasibility. (Table 5, Table 6)
In the first round of survey, we received 134 proposals
for modifications of previously listed measures or for
additional measures. These covered funding priorities,
research cooperation, capacity building and knowledge
transfer, access, visibility and awareness, incentives, and
structural reforms and regulations. After careful analysis,
the proposals were developed into a list of 50 measures
for the second round of survey.
A regulatory instrument to promote R&D for neglected
diseases
Further to the questions on causes and measures, it was
of interest to learn whether the panelists considered it
desirable and feasible to have a regulatory instrument to
promote R&D for neglected diseases in which these
measures might be absorbed. In both rounds of survey,
the respondents found the option (very) desirable as
well as feasible. (Table 7)
Cross-tabulations by professional affiliation on the
basis of aggregated positive replies (very desirable/desir-
able) revealed that, in the first round of survey, most sub-
groups were supportive of the concept of a regulatory
instrument (90% academia, 100% national government/
parliament, 100% international organizations, 93.8% non-
governmental organizations and 100% “other”)O ft h e
experts affiliated with industry, 58.3% expressed a posi-
tive opinion on a regulatory instrument, while 41.6% said
it was undesirable or very undesirable. In the second
round of survey, experts with affiliations in academia,
national government/parliament, non-governmental
organization and other affiliations again gave over 90% of
support for a regulatory instrument. Opinions in the sub-
group “industry” remained diverse (66.7% for and 33.3%
against a regulatory instrument). Also, representatives of
international organizations were less agreed in the
second round; one representative considered it desirable,
one undesirable and two expressed no judgment. Simi-
larly, the two experts affiliated with a public private part-
nership were disagreed on the subject.
In both rounds of survey, the feasibility of a regulatory
instrument was judged positively by experts from acade-
mia (80%/85.7%), national governments/parliaments
(83.3%/100%) and from NGOs (87.6%/83.3%) In con-
trast, while 80% of the respondents affiliated with an
international organization had considered a regulatory
instrument to be a feasible option in the first round,
three out of four experts in this subgroup said it was
possibly unfeasible in the second round. Experts
Table 2 Effectiveness of orphan drug laws and incentives
very effective effective ineffective very ineffective no judgment
Orphan drug laws 7.1% 54.3% 17.1% 0% 21.4%
Market exclusivity 22.1% 33.8% 17.6% 4.4% 22.1%
Tax credits 14.5% 47.8% 10.1% 1.4% 26.1%
Protocol assistance 13.2% 41.2% 14.7% 0% 30.9%
Fee reduction/Fee waivers 8.8% 41.2% 23.5% 1.5% 25.0%
Fehr et al. BMC Health Services Research 2011, 11:312
http://www.biomedcentral.com/1472-6963/11/312
Page 6 of 13Table 3 Desirability of orphan drug incentives for neglected diseases
%( n ) %( n ) %( n ) %( n ) %( n )
very desirable desirable undesirable very undesirable no judgment Total valid % (n) Total N (Missing)
Market exclusivity Round I 7,8% (9) 19,1% (22) 26,1% (30) 20,9% (24) 26,1% (30) 100% (115) 159 (44)
Round II 3,6% (2) 20,0% (11) 36,4% (20) 21,8% (12) 18,2% (10) 100% (55) 77 (22)
Tax credits Round I 14,2% (16) 48,7% (55) 6,2% (7) 1,8% (2) 29,2% (33) 100% (113) 159 (46)
Round II 20,4% (11) 46,3% (25) 11,1% (6) 3,7% (2) 18,5% (10) 100% (54) 77 (23)
Protocol assistance Round I 25,9% (30) 44,0% (51) 4,3% (5) 0,0% (0) 25,9% (30) 100% (116) 159 (43)
Round II 33,9% (19) 55,4% (31) 3,6% (2) 0,0% (0) 7,1% (4) 100% (56) 77 (21)
Fee reduction/Fee waivers (e.g. for marketing approval, scientific advice) Round I 27,0% (31) 53,9% (62) 3,5% (4) 0,9% (1) 14,8% (17) 100% (115) 159 (44)
Round II 28,1% (16) 56,1% (32) 7,0% (4) 0,0% (0) 8,8% (5) 100% (57) 77 (20)
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3Table 4 Feasibility of orphan drug incentives for neglected diseases
% (n) % (n) % (n) % (n) % (n)
very (definitely)
feasible
feasible unfeasible definitely
unfeasible
no
judgment
Total valid %
(n)
Total N
(Missing)
Market exclusivity Round
I
10% (11) 28,2%
(31)
20,9%
(23)
2,7% (3) 38,2% (42) 110 159 (49)
Round
II
13.7% (7) 27.5%
(14)
27.5% (14) 2.0% (1) 29.4% (15) 51 77 (26)
Tax credits Round
I
21.8% (24) 40,0%
(44)
4,5% (5) 2,7% (3) 30,9% (34) 110 159 (49)
Round
II
35.3% (18) 37.3%
(19)
5.9% (3) 2.0 (1) 19.6% (10) 51 77 (26)
Protocol assistance Round
I
32.7% (36) 44,5%
(49)
1.8% (2) 0,0% (0) 20.9% (23) 110 159 (50)
Round
II
35,3% (18) 52.9%
(27)
3.9% (2) 0.0% (0) 7.8% (4) 51 77 (26)
Fee reduction/Fee waivers (e.g. for marketing approval, scientific
advice)
Round
I
26,6% (29) 51.4%
(56)
4.6% (5) 0,9% (1) 16.5% (18) 110 159 (49)
Round
II
23.1% (12) 50.0%
(26)
11.5% (6) 0.0% (0) 15.4% (8) 52 77 (25)
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3Table 5 Desirability of MRDT proposals to promote R&D for neglected diseases
% (n) % (n) % (n) % (n) % (n)
very desirable desirable undesirable very undesirable no judgment Total valid % (n) Total N (Missing)
Prize funds with prizes awarded based on degree of innovation Round I 35.6% (42) 44.1% (52) 6.8% (8) 3.4% (4) 10.2% (12) 118 159 (41)
Round II 33.9% (19) 35.7% (20) 12.5% (7) 3.6% (2) 14.3% (8) 56 77 (21)
Obligation for national governments to invest into neglected disease R&D Round I 48.3% (56) 38.8% (45) 6.9% (8) 1.7% (2) 4.3% (5) 116 159 (43)
Round II 40.4% (23) 36.8% (21) 14.0% (8) 1.8% (1) 7.0% (4) 57 77 (20)
Separation of innovation incentives from drug prices Round I 38.8% (45) 30.2% (35) 4.3% (5) 4.3% (5) 22.4% (26) 116 159 (43)
Round II 38.2% (21) 27.3% (15) 12.7%(7) 5.5% (3) 16.4% (9) 55 77 (22)
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3Table 6 Feasibility of MRDT proposals to promote R&D for neglected diseases
% (n) % (n) % (n) % (n) % (n)
definitely feasible feasible unfeasible definitely unfeasible no judgment Total valid % (n) Total N
Prize funds with prizes awarded based on degree of innovation Round I 20.9% (23) 60.0% (23) 4.5% (5) 0.9% (1) 13.6% (15) 110 159
Round II 30.8% (16) 48.1% (25) 11.5% (6) 1.9% (1) 7.7% (4) 52 77 (25)
Obligation for national governments to invest into neglected disease R&D Round I 28.2% (31) 41.8% (46) 20.0% (22) 5.5% (6) 4.5% (5) 110 159 (49)
Round II 11.3% (6) 43.4% (23) 35.8% (19) 3.8% (2) 5.7% (3) 53 77 (24)
Separation of innovation incentives from drug prices Round I 12.6% (14) 39.6% (44) 11.7% (13) 6.3% (7) 29.7% (33) 111 159 (48)
Round II 15.1% (8) 41.5% (22) 11.3% (6) 9.4% (5) 22.6% (12) 53 77 (24)
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3affiliated with industry were equally skeptical in their
assessment of the instrument’s feasibility (50%/66.7%).
Discussion
Method
The Delphi method and its online implementation were
well received. A large number of experts participated in
the survey over a period of five months. They devoted
time and effort to fill out two online questionnaires and
contributed new items as well as extensive - also critical! -
comments. The latter ranged from “not sure what you can
deduce from this listing - most listed items are clearly
important, and there’s much overlap, so what are we going
to learn from “important” versus “very important"?” to
“The results will [be] interesting and helpful for policy
development” or: “Very interesting and useful. I guess
sometimes one would like more nuanced options for a
more appropriate answer”.
As we have shown in the first paragraph of the Results
section, the sample was not balanced in terms of profes-
sional backgrounds, professional affiliations or the place of
residence. The aim of the survey was to gather as broad a
spectrum of perspectives as possible. The sample selection
was purposive insofar as we chose specific sources from
which to gather a panel of interested experts, such as rele-
vant publications, conferences, hearings etc.. Prior to the
first round of the survey, we could only assume the distri-
bution of experts in the demographic categories. Since it
was impossible to predict participation and attrition rates
at the onset of the study, we did not attempt to reduce and
adjust the initial panel to represent a balanced sample. We
do not dare to anticipate how and if the results of the
study may have differed if the panel had been more
balanced. However, we observed variations within groups
in cross-tabulations which suggest that the assessments
made by the experts may not necessarily be linked to pro-
fessional affiliations.
Results
The survey facilitated the quantification and correlation
of views far beyond what can be reproduced in this
paper. Its outcome underlined that insufficient funding
for R&D for neglected diseases is one of the most impor-
tant causes for the treatment deficit. Yet it is by no
means the only important cause: there was only one item
(no/ineffective drugs for NDs) in the first round, and two
items (no/inadequate research coordination and disease-
specific research difficulties) in the second round that
received less than 80% of aggregated positive responses
(most important/important) by all participating experts.
Similarly, while respondents from all professional affilia-
tions chose funding issues as most important in the first
round, they suggested 98 additional items, which formed
the basis for the extension of the list of causes in the sec-
ond round. Consequently, funding issues became one of
several causes that received high priority in the different
professional affiliations. This process and its outcome
underline the complexity of the issue and the need to
uphold multifocal strategies that will increase awareness,
reduce poverty, adjust R&D priorities to include NDs,
increase and sustain public and private sector funding,
and promote health as well as research infrastructure in
endemic countries.
Certainly, no single mechanism or regulatory instru-
ment can cover this broad range of challenges. The parti-
cipants of the survey offered a diversity of comments on
the desirability and feasibility of a regulatory instrument,
including: “This is a purely national decision unlikely to
be easily introduced into legislative bodies, but definitely
worth trying. Once a few countries install some such
instrument others will follow."; “would best be done
under the auspices of the WHO, would cover all aspects
from discovery to delivery, with follow up monitoring";
“We have too much regulation already and implementa-
tion on a global basis is simply not practicable”.
Various modifications to orphan drug laws for the ben-
efit of NDs have been suggested in recent years such as
transferable market exclusivity [34,35], or the definition
of all NDs as orphan diseases [25]. The survey revealed
that incentives such as tax credits, fee waivers and proto-
col assistance were also considered promising to promote
R&D into drugs for neglected diseases. In view of the fact
that a majority of the respondents advocated a regulatory
instrument to promote R&D for neglected diseases, it
Table 7 A regulatory instrument to promote R&D for neglected diseases: Round I and II
very desirable desirable undesirable very undesirable no judgment n = missing** Median***
Desirability* 44.2% (49.1%) 44.2% (37.7%) 7.1% (3.8%) 1.8% (3.8%) 2.7% (5.7%) 113 (53) 46
(24)
2.00 (1.00)
very (definitely) feasible feasible unfeasible definitely unfeasible no judgment n missing** Median***
Feasibility* 14.2% (18.9%) 63.7% (60.4%) 8.0% (15.1%) 3.5% (5.7%) 10.6% (0.0%) 113 (53) 46
(24)
2.00 (2.00)
Results of the second round of the survey are shown in brackets
*1 = very desirable/very (definitely) feasible, 2 = desirable/feasible, 3 = undesirable/unfeasible, 4 = very undesirable/definitely unfeasible, 5 = no judgment
**Participants who abandoned the questionnaire prior to this question or who did not answer the question
*** Excludes 5 = no judgment
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Page 11 of 13may be of interest to further explore whether it would be
beneficial to extend selected orphan drug incentives to
neglected diseases [36]. Correspondingly, for several
years, the concept of a biomedical R&D treaty has been
debated at international levels [26,28,29,37-39], and dis-
cussed in the scientific community [34,40-46]. One of its
key concepts, i.e. national funding obligations for medical
R&D, was considered desirable by a majority of the sur-
vey participants. The feasibility of this proposal, however,
was judged more cautiously.
The respondents were not asked, however, to assess
orphan drug acts or the MRDT for neglected diseases as
such. This, on the one hand, precludes a comprehensive
answer to the question of their desirability and feasibility
for ND research and development. On the other hand, the
separation of individual measures from specific regulatory
instruments was part of the survey’s concept to enable us
to learn which measures are attractive and practicable in
the eyes of the respondents. It may thus be of interest to
carry forward, expand and focus the research, perhaps with
a similar methodology, to engage experts and stakeholders
in determining which measures could contribute to a
future instrument to promote R&D for neglected diseases.
Conclusions
The treatment deficit for neglected diseases can neither be
attributed to a single cause, nor can it be remedied by a
single measure. Both orphan drug acts and the MRDT are
controversial approaches to promoting neglected disease
R&D. The ongoing debate on the two concepts points to a
strong interest in a regulatory instrument, which we could
confirm in our Delphi survey. Such instrument may not
rely on the same incentives as orphan drug regulations, or
completely restructure medical R&D funding as proposed
in the MRDT. Still, if it included mechanisms to provide
sufficient and sustainable funding for effective, affordable
and field-sensitive diagnostics and treatments, facilitated
research cooperation and increased awareness for NDs on
health policy agendas, it would express the same political
will to guarantee equitable health care for patients with
neglected diseases as orphan drug regulations intended for
patients with rare diseases.
It is recommended that a Policy Delphi is followed by
a working group which may utilize the results to formu-
late relevant policy recommendations. [30] The data
which have been gathered in the survey will be analyzed
further so that the valuable input of the respondents
will contribute to the ongoing search for mechanisms to
promote R&D for neglected diseases.
Additional material
Additional file 1: Questionnaire Round I. Questionnaire of the first
round of the Delphi survey.
Additional file 2: Questionnaire Round II. Questionnaire of the second
round of the Delphi survey.
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